What is the prognosis of Hürthle cell carcinoma?

Updated: May 14, 2020
  • Author: Pramod K Sharma, MD; Chief Editor: Arlen D Meyers, MD, MBA  more...
  • Print


Patients with Hürthle cell carcinoma should be monitored closely for recurrent and metastatic disease. The overall 5-year survival rate is 50-60%. Because tumors do not take up iodine and are not TSH sensitive, thyroid suppression and radioiodine therapy have little value. External-beam radiation therapy can used to treat metastatic disease. Surgery is the mainstay of treatment.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!